What is Luminopia?
Founded in 2016 and operating as an Innovation Partner of Boston Children's Hospital, Luminopia is at the forefront of developing digital therapeutics for significant neuro-visual disorders. The company's mission is to create engaging, rigorously evaluated treatments aimed at FDA approval. Its lead product, Luminopia One, is specifically designed to enhance vision in children suffering from amblyopia, a prevalent cause of visual impairment in pediatric populations. This focus positions Luminopia as a key player in the intersection of digital health and ophthalmology.
How much funding has Luminopia raised?
Luminopia has raised a total of $26.5M across 2 funding rounds:
Angel/Seed
$10.5M
Series A
$16M
Angel/Seed (2022): $10.5M with participation from SSI Strategy, Sony Innovation Fund, ShangBay Capital, and The Vertical Group
Series A (2023): $16M led by Broadfin Capital, ShangBay Capital, and US Venture Partners
Key Investors in Luminopia
Broadfin Capital
Broadfin Capital is a healthcare-focused investment firm specializing in unique investment opportunities within the healthcare sector, offering comprehensive investment strategies and financial planning.
ShangBay Capital
ShangBay Capital is a venture capital firm specializing in medical devices, biotechnology, and healthcare, with a focus on seed and early-stage industries.
US Venture Partners
U.S. Venture Partners (USVP) is a prominent Silicon Valley venture capital firm dedicated to collaborating with entrepreneurs, specializing in early-stage investments across cybersecurity, enterprise software, consumer products, and healthcare.
What's next for Luminopia?
The recent major strategic investment signals a pivotal growth phase for Luminopia, likely enabling the company to accelerate the development and commercialization of Luminopia One. This capital infusion is expected to support further clinical validation, regulatory submissions, and market expansion efforts. With a clear focus on addressing unmet needs in pediatric vision care, Luminopia is poised to leverage this backing to solidify its position as a leader in digital therapeutics for neuro-visual disorders.
See full Luminopia company page
